AB001 is a novel PSMA-targeted radioligand therapy designed to treat metastatic prostate cancer with potentially higher tumor dose rates and lower normal tissue toxicity. The phase 1 trial will enroll ...

The episode also underscores the role of artificial intelligence in prostate imaging. In this episode of Pearls & Perspectives, Amy Pearlman, MD, speaks with Dan Sperling, MD, DABR, a board-certified ...

Inlexzo, a gemcitabine intravesical system, is approved for BCG-unresponsive NMIBC, offering extended local drug delivery for up to 14 cycles. The SunRISe-1 trial showed an 82.4% complete response ...

William C. Huang, MD, highlights data from a long-term extension study of the OPTIMA II trial. In a recent interview with Urology Times®, William C. Huang, MD, outlined the key findings and ...

"Liquid biopsy analysis provides a noninvasive and facile tool for early detection, diagnosis, and recurrence surveillance of urological cancer," writes Jim Lu, MD, PhD.

IDE397 combined with sacituzumab govitecan showed promising efficacy in MTAP-deletion urothelial carcinoma, with high disease control rates in both dose cohorts. The combination therapy's efficacy ...

Alpha DaRT technology diffuses alpha-emitting atoms within tumors, overcoming alpha particles' short travel range limitation. The technology shows promise in prostate and bladder cancer, offering ...

Cretostimogene grenadenorepvec shows a 24-month complete response rate of 41.8% in high-risk BCG-unresponsive patients with NMIBC, with 90% of 12-month responders maintaining CR. The BOND-003 trial ...

The Signatera ctDNA test predicts which MIBC patients benefit from adjuvant atezolizumab, showing significant DFS and OS improvements in MRD-positive patients. The IMvigor011 trial enrolled 760 ...

Continuation of ARPI with [177Lu]Lu-PSMA-617 in ARPI-refractory mCRPC patients does not improve PSA response or overall survival. Patients receiving ARPI were more likely to complete all treatment ...

AI model detects early signs of prostate cancer in biopsies before histological changes are apparent, outperforming pathologists in over 80% of cases. The study involved 213 patients, with the AI ...

The Decipher Prostate Genomic Classifier predicts docetaxel benefit in metastatic prostate cancer, especially in patients with high Decipher scores. High Decipher scores correlate with improved ...